Extension of Tocilizumab Dose Intervals in Patients with Low to Moderate Disease Activity Rheumatoid Arthritis using IL-6 Serum Level as Starting Criteria.

Extension of Tocilizumab Dose Intervals in Patients with Low to Moderate Disease Activity Rheumatoid Arthritis using IL-6 Serum Level as Starting Criteria. - Extension of Tocilizumab Dose Intervals in Patients with Rheumatoid Arthritis using IL-6 Serum Level Criteria.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008404

Enrollment

Registered

2012-07-12

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Extension of Tocilizumab Dose Intervals

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Rheumatoid arthritis diagnosed by ACR/EULAR new classification criteria for RA. 2) Patients diagnosed as low disease activity state of RA (CDAI10 or less) 3) Patients with IL-6 serum concentration(35 pg/mL or less)

Exclusion criteria

Exclusion criteria: 1) Patient who has no contraindications to methotrexate or to tocilizumab. 2) Patients who are inadequate to enter this trail due to the other reasons by physicians judgments.

Design outcomes

Primary

Measure	Time frame
The rate of patients completed 48 weeks with tocilizumab 8-weeks dose intervals.	—

Countries

Japan

Contacts

Public ContactYasuhiko Kita

Japan Labour Health and Welfare Organization, Department of Rheumatology

kitayas@yokohamah.rofuku.go.jp045-474-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026